Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Net Income (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Net Income data on record, last reported at -$39.2 million in Q4 2025.

  • For Q4 2025, Net Income fell 3644.8% year-over-year to -$39.2 million; the TTM value through Dec 2025 reached -$143.7 million, down 319.09%, while the annual FY2025 figure was -$143.7 million, 319.09% down from the prior year.
  • Net Income reached -$39.2 million in Q4 2025 per TRDA's latest filing, up from -$44.1 million in the prior quarter.
  • Across five years, Net Income topped out at $55.0 million in Q2 2024 and bottomed at -$44.1 million in Q3 2025.
  • Average Net Income over 4 years is -$11.2 million, with a median of -$19.5 million recorded in 2022.
  • Peak YoY movement for Net Income: skyrocketed 452.52% in 2024, then tumbled 3644.8% in 2025.
  • A 4-year view of Net Income shows it stood at -$24.6 million in 2022, then soared by 61.25% to -$9.5 million in 2023, then surged by 111.58% to $1.1 million in 2024, then crashed by 3644.8% to -$39.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were -$39.2 million in Q4 2025, -$44.1 million in Q3 2025, and -$43.1 million in Q2 2025.